Skip to Main Content


Richard Bucala, MD, PhD

Waldemar Von Zedtwitz Professor of Medicine (Rheumatology) and Professor of Pathology and of Epidemiology (Microbial Diseases); Chief, Rheumatology, Allergy, & Immunology; Rheumatologist in Chief, Rheumatology; Affiliated Faculty, Yale Institute for Global Health

Contact Information

Richard Bucala, MD, PhD

Patient Care Location

Office Location



Richard Bucala, MD, PhD, is a Professor of Medicine, Pathology, and Epidemiology & Public Health. He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally. Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF antibody developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders. He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project. Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

Education & Training

  • Fellow
    Hospital for Special Surgery (1991)
  • Resident
    Brigham & Women's Hospital/Harvard Medical School (1988)
  • MD
    Cornell College (1986)
  • PhD
    Rockefeller University (1985)
  • Visiting Fellow
    Institut Pasteur, Paris (1985)
  • BS
    Yale University (1979)
  • MS
    Yale University (1979)


  • Genetic studies of human host susceptibility to tuberculosis
    South Africa 2010
    Genetic studies of human host susceptibility to tuberculosis
  • Genetic Susceptibility to Leishmania
    Colombia 2008
    The Bucala group is investigating the genetic susceptibility to the parasitic infection Leishmania in collaboration with researchers in Cali, Colombia.
  • Genetic studies of human host susceptibility to Leishmaniasis
    Cali, Valle del Cauca, Colombia 2005
    Genetic studies of human host susceptibility to Leishmaniasis
  • Genetic epidemiology studies
    Kenya; Zambia 2003
    Role of innate immunity in malaria infection

Honors & Recognition

American Association of Physicians2009
American Society for Clinical Investigation1996

Professional Service

Arthritis & RheumatologyEditor-in-Chief2015 - Present
Journal of ImmunologyAssociate Editor2010 - 2015
Alumni Schools CommitteeMember2008 - 2012
NIHNIH Biodefense and Chemical Countermeasures2006 - 2012

Departments & Organizations